ACM
ROIV icon

Atalaya Capital Management’s Roivant Sciences ROIV Stock Holding History

Atalaya Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$18.1M Buy
1,714,843
+1,677,367
+4,476% +$18.4M 40.31% 1
2024
Q1 		$395K Hold
37,476
– – 0.46% 18
2023
Q4 		$421K Hold
37,476
– – 0.61% 19
2023
Q3 		$438K Buy
+37,476
New +$424K 0.49% 25

Other funds holding ROIV

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Atalaya Capital Management's ROIV Position: Q2 2024 in Review

Atalaya Capital Management increased its Roivant Sciences (ROIV) stake by 4,476% in Q2 2024, buying an estimated $18.4M and bringing the position to 1,714,843 shares worth $18.1M. The position accounts for 40.31% of the portfolio, ranked #1.

Atalaya Capital Management first reported a position in ROIV in Q3 2023 and has held it in 4 quarters since. 293 funds tracked by Wall St. Rank hold ROIV as of Q2 2024.

  • Atalaya Capital Management held 1,714,843 shares of Roivant Sciences worth $18.1M as of Q2 2024.
  • Atalaya Capital Management bought 1,677,367 Roivant Sciences shares in Q2 2024, an estimated $18.4M.
  • Roivant Sciences made up 40.31% of Atalaya Capital Management's portfolio in Q2 2024, its #1 holding.
  • Atalaya Capital Management first reported a position in Roivant Sciences in Q3 2023 and has held it in 4 quarters since.
  • 293 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2024.

Based on Atalaya Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.